CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload

Publisher： Karger

E-ISSN： 2296-5262|39|7-8|424-431

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.39, Iss.7-8, 2016-06, pp. : 424-431

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia

By  

TRANSFUSION, Vol. 54, Iss. 6, 2014-06 ,pp. : 1542-1551

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload

By  

TRANSFUSION, Vol. 55, Iss. 7, 2015-07 ,pp. : 1613-1620

John Wiley & Sons Inc

Access to resources Recommend Favorite

Two-Year Analysis of Efficacy and Safety of Deferasirox Treatment for Transfusional Iron Overload in Sickle Cell Anemia Patients

By  

Acta Haematologica, Vol. 128, Iss. 2, 2012-06 ,pp. : 113-118

Karger

Access to resources Recommend Favorite

Deferasirox (Exjade®) for the Treatment of Iron Overload

By  

Acta Haematologica, Vol. 122, Iss. 2-3, 2009-11 ,pp. : 165-173

Karger

Access to resources Recommend Favorite

The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 7-1048, Iss. 2, 1996-08 ,pp. : 288-299

John Wiley & Sons Inc

Access to resources Recommend Favorite